While the Publication bias was suspected, the adjusted effect size using trim and fill method was similar. b.
Imprecision caused by the small number of events; which caused wide CIs with lower boundaries close to the null effect.
The certainty in evidence is rated as high for the outcome of serious infections for the following reasons: (i) the evidence was derived from RCTs, (ii) the meta-analytic effect estimates were precise, (iii) the results are consistent (heterogeneity was low or moderate across studies); and (iv) the vast majority of the RCTs included in our study are characterized by low or unclear RoB, as assessed with the Cochrane Collaboration's tool. While the Publication bias was suspected, the adjusted effect size using trim and fill method was similar. On the other hand, the certainty of evidence was rated down to "moderate" for the outcomes of opportunistic infections and malignancy due to imprecision caused by the small number of events; which caused wide CIs with lower boundaries close to the null effect. 13 (Anakinra or "anti-IL-1 beta monoclonal antibod*" or "anti-IL-1beta monoclonal antibod*" or "anti-interleukin 1 beta monoclonal antibod*" or "anti-interleukin 1beta monoclonal antibod*" or Brodalumab or Canakinumab or Clazakizumab or Guselkumab or "IL-1 receptor antagonist*" or "IL-1 receptor block*" or "IL-12" or "IL-17" or "IL-17A" or "IL-1b inhibitor*" or "IL-23p19" or "IL-23p40" or "IL-6" or "IL-6 receptor antibod*" or "interleukin 1 receptor antagonist*" or "interleukin 1 receptor block*" or "interleukin-12" or "interleukin-17" or "interleukin-17A" or "interleukin-1b inhibitor*" or "interleukin-23p19" or "interleukin-23p40" or "interleukin-6" or "interleukin-6 receptor antibod*" or Ixekizumab or olokizumab or Rilonacept or Secukinumab or Tildrakizumab or Tocilizumab or Ustekinumab 
